Zobrazeno 1 - 10
of 1 792
pro vyhledávání: '"Norris, A. C."'
Autor:
Norris, David C., Triska, Markus
We present, as a pure Prolog program, the first executable specification of the 3 + 3 dose-escalation protocol commonly used in early-phase oncology drug development. In this program, the imperative operations of the protocol emerge as consequences o
Externí odkaz:
http://arxiv.org/abs/2402.08334
Autor:
Jones, Christopher E., Dangas, Georgios, Norris, Adriana C., Koenig, Madeleine, Li, Dar-Yin, Shue, Taylor M., Athanasiadis, Antonis, Barbosa, Luana, Zhou, Yichen, Levenson, Kenneth C., Zou, Chenhui, de Jong, Ype P., Michailidis, Eleftherios
Publikováno v:
In Virology December 2024 600
Autor:
Burton, Brittany N., Adeola, Janet O., Do, Veena M., Milam, Adam J., Cannesson, Maxime, Norris, Keith C., Lopez, Nicole E., Gabriel, Rodney A.
Publikováno v:
In The Joint Commission Journal on Quality and Patient Safety June 2024 50(6):416-424
Autor:
Norris, Adriana C., Mansueto, Alexander J., Jimenez, Mariana, Yazlovitskaya, Eugenia M., Jain, Bhawik K., Graham, Todd R.
Publikováno v:
In BBA - Molecular Cell Research April 2024 1871(4)
Autor:
Mansfield, Lisa N., Carson, Savanna L., Castellon-Lopez, Yelba, Casillas, Alejandra, Morris, D’Ann, Ntekume, Ejiro, Barron, Juan, Norris, Keith C., Brown, Arleen F.
Publikováno v:
Ethnicity & Disease, 2022 Oct 01. 32(4), 341-350.
Externí odkaz:
https://www.jstor.org/stable/48713493
Autor:
Jones, Malcolm, Hoague, Danielle, Spriggs, Raenita, Catalan, Elijah, Adams, Naomi, Watkins, Timothy, Tripati, Aradhna, Norris, Keith C.
Publikováno v:
Ethnicity & Disease, 2022 Oct 01. 32(4), 333-340.
Externí odkaz:
https://www.jstor.org/stable/48713492
Autor:
Norris, David C.
If explicit, formal consideration of clinical pharmacology at all informs the design and conduct of modern oncology dose-finding trials, the designs themselves hardly attest to this. Yet in conducting a trial, investigators affirm that they hold reas
Externí odkaz:
http://arxiv.org/abs/2012.05301
Autor:
Norris, David C.
The commonplace description of phase 1 clinical trials in oncology as "primarily concerned with safety" is belied by their near universal adoption of dose-escalation practices which are inherently unsafe. In contrast with dose titration, cohort-wise
Externí odkaz:
http://arxiv.org/abs/2004.12755
Autor:
Koyama, Alain K., Nee, Robert, Yu, Wei, Choudhury, Devasmita, Heng, Fei, Cheung, Alfred K., Norris, Keith C., Cho, Monique E., Yan, Guofen
Publikováno v:
In American Journal of Kidney Diseases December 2023 82(6):706-714